Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes
Iliana C. Lega, Susan E. Bronskill, Michael A. Campitelli, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 11, pp. 2394-2404
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, et al.
Kidney International Reports (2022) Vol. 7, Iss. 7, pp. 1463-1476
Open Access | Times Cited: 130
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 435-447
Open Access | Times Cited: 83
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
Andrew McGovern, Michael A. Hogg, Beverley M. Shields, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 1, pp. e001238-e001238
Open Access | Times Cited: 74
SGLT2 Inhibitors: The Sweet Success for Kidneys
Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, et al.
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 369-384
Open Access | Times Cited: 29
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 16, pp. 1568-1578
Closed Access | Times Cited: 13
(+)-Catechin ameliorates diabetic nephropathy injury by inhibiting endoplasmic reticulum stress-related NLRP3-mediated inflammation
Xiwen Zhang, Zhihao Huo, Xiaotong Jia, et al.
Food & Function (2024) Vol. 15, Iss. 10, pp. 5450-5465
Closed Access | Times Cited: 8
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
Seung Jin Han, Kyoung Hwa Ha, Nami Lee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 682-691
Open Access | Times Cited: 67
Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors
Kristin Engelhardt, McKenzie Ferguson, Jennifer L. Rosselli
Annals of Pharmacotherapy (2020) Vol. 55, Iss. 4, pp. 543-548
Closed Access | Times Cited: 52
Complicated urinary tract infections with diabetes mellitus
Jun Kamei, Shingo Yamamoto
Journal of Infection and Chemotherapy (2021) Vol. 27, Iss. 8, pp. 1131-1136
Closed Access | Times Cited: 43
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer
Cho‐Han Chiang, Cho‐Hung Chiang, Cho‐Hsien Chiang, et al.
Heart (2022) Vol. 109, Iss. 6, pp. 470-477
Open Access | Times Cited: 32
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
Samuel Seidu, Xavier Cos, Stephen Brunton, et al.
Primary care diabetes (2022) Vol. 16, Iss. 2, pp. 223-244
Open Access | Times Cited: 30
Practical considerations for the use of SGLT‐2 inhibitors in the Asia–Pacific countries—An expert consensus statement
Adrian Liew, Aida Lydia, Bien J. Matawaran, et al.
Nephrology (2023) Vol. 28, Iss. 8, pp. 415-424
Open Access | Times Cited: 17
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C. J. Dekkers, Ron T. Gansevoort
Nephrology Dialysis Transplantation (2019) Vol. 35, Iss. Supplement_1, pp. i33-i42
Open Access | Times Cited: 51
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
M Hanefeld, Holger Fleischmann, Thorsten Siegmund, et al.
Diabetes Therapy (2020) Vol. 11, Iss. 8, pp. 1645-1666
Open Access | Times Cited: 49
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2019) Vol. 127, Iss. S 01, pp. S73-S92
Open Access | Times Cited: 47
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Angela Dardano, Roberto Miccoli, Cristina Bianchi, et al.
Diabetes Research and Clinical Practice (2020) Vol. 162, pp. 108112-108112
Open Access | Times Cited: 39
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction
Jawad H. Butt, Kieran F. Docherty, Mark C. Petrie, et al.
JAMA Cardiology (2021) Vol. 6, Iss. 6, pp. 678-678
Open Access | Times Cited: 39
ThinkCascades: A Tool for Identifying Clinically Important Prescribing Cascades Affecting Older People
Lisa McCarthy, Rachel Savage, Kieran Dalton, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 829-840
Open Access | Times Cited: 26
SGLT2 Inhibitors and Safety in Older Patients
Rena Pollack, Avivit Cahn
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 635-643
Closed Access | Times Cited: 22
Assessing Heterogeneity of Treatment Effect in Real-World Data
Jodi B Segal, Ravi Varadhan, Rolf H. H. Groenwold, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 536-544
Open Access | Times Cited: 15
Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Zhigui Zheng, Dongyuan He, Jianguo Chen, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 209-225
Closed Access | Times Cited: 15
Use of sodium–glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation
Darren Lau, Neesh Pannu, Roseanne O. Yeung, et al.
CMAJ Open (2023) Vol. 11, Iss. 1, pp. E101-E109
Open Access | Times Cited: 13
Prescribing Cascades with Recommendations to Prevent or Reverse Them: A Systematic Review
Oriane Adrien, Atiya K. Mohammad, Jacqueline G. Hugtenburg, et al.
Drugs & Aging (2023) Vol. 40, Iss. 12, pp. 1085-1100
Open Access | Times Cited: 13
Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study
Gassan Moady, Igor Yakubovich, Shaul Atar
Journal of Cardiovascular Pharmacology and Therapeutics (2024) Vol. 29
Open Access | Times Cited: 5
Advances in the study of the correlation between balanoposthitis and skin microecology
Mingyue Wang, Xinghua Gao, Li Zhang
Frontiers in Microbiology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top